We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Advanced Melanoma

Journal Scan / Research · April 07, 2021

Neoadjuvant Ipilimumab Plus Nivolumab in Synchronous Clinical Stage III Melanoma

European Journal of Cancer

 

Additional Info

European Journal of Cancer
Neoadjuvant Ipilimumab Plus Nivolumab in Synchronous Clinical Stage III Melanoma
Eur. J. Cancer 2021 May 01;148(xx)51-57, JM Versluis, ILM Reijers, EA Rozeman, AM Menzies, ACJ van Akkooi, MW Wouters, S Ch'ng, RPM Saw, RA Scolyer, BA van de Wiel, B Schilling, GV Long, CU Blank

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading